Leqvio and Repatha to spearhead lipid-modifying agents market resurgence
The lipid-modifying agents market, which had seen a dramatic decline over the past decade, is now set for a spectacular revival, driven by the innovating therapies Leqvio (inclisiran) from Swiss pharma giant Novartis (NOVN: VX) and Repatha (evolocumab) from US biotech Amgen (Nasdaq: AMGN).
These two treatments are forecast to spreadhead the market’s resurgence, bringing it back to prominence by 2030, according to pharma analytics company GlobalData.
The lipid-modifying agents market has been facing a significant downturn since 2011 due to the expiration of patents of blockbuster drugs. Among the most notable losses was Lipitor (atorvastatin) from Viatris (Nasdaq: VTRS), which accounted for a staggering $11 billion in sales in 2011, nearly 39% of the market. Following its loss of exclusivity, Lipitor’s sales plummeted by 56% within just a year due to intense competition from generic versions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze